Relay Therapeutics Upsizes ATM to $463M, Reports $911M Cash and Pipeline Progress
RLAY has more than doubled off its 52-week low of $3.025.
Summary
Relay Therapeutics increased its ATM program to $463 million, with $213 million in new shares available for sale, while reporting $911 million in cash and advancing its zovegalisib program in breast cancer and vascular anomalies.
Key Events · Financing and Capital Events · RLAY
-
ATM Program Upsized to $463M
Amendment increases total ATM capacity from $250M to $462.98M, with $212.98M in new shares available for sale through TD Cowen; $162.98M already sold under prior agreement.
-
Q2 2026 Cash Position at $910.9M
Cash, equivalents, and investments rose to $910.9M from $642.1M in Q1, primarily due to $316M follow-on offering in May 2026; runway extends into 2029.
-
Zovegalisib Triplet Selected for 1L Breast Cancer
Zovegalisib plus atirmociclib chosen as go-forward regimen; Phase 3 trial in endocrine-sensitive patients expected to start in early 2027, subject to regulatory feedback.
-
Vascular Anomalies Data Presented
Initial Phase 1/2 data showed 60% volumetric response rate at 12 weeks; expansion cohorts opened for adults/adolescents, dose escalation ongoing for pediatric patients.
Analysis · RLAY · Life Sciences
Relay Therapeutics amended its at-the-market sales agreement with TD Cowen, increasing the total program size from $250 million to approximately $463 million. The company has already sold about $163 million under the original agreement, leaving up to $213 million in additional shares available for sale. This upsizing provides significant financial flexibility but introduces potential dilution for existing shareholders. Separately, the company reported Q2 2026 financial results: $910.9 million in cash, cash equivalents, and investments, extending its runway into 2029. The quarter saw a net loss of $83.7 million, with R&D expenses rising to $76.5 million, driven by clinical trial costs. Pipeline updates include the selection of zovegalisib plus atirmociclib as the go-forward triplet regimen for frontline breast cancer, with a Phase 3 trial expected in early 2027, and positive initial data in vascular anomalies. The strong cash position, bolstered by a $316 million follow-on offering in May 2026, supports these development plans, but the ATM amendment signals ongoing capital needs.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RLAY was trading at $19.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $3.03 to $20.79. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.